Skip to main
NERV

Minerva Neurosciences (NERV) Stock Forecast & Price Target

Minerva Neurosciences (NERV) Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 50%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Minerva Neurosciences is a potential promising pharmaceutical company with its product candidate, Roluperidone, showing positive results for treating negative symptoms in schizophrenia patients. With anticipated results of the phase 3 trial in 2027, the drug could potentially be the first approved therapy to target negative symptoms and potentially launch in 2029. Additionally, the expertise of the company's Chief Operating Officer in the life sciences industry adds to the potential success of the drug.

Bears say

Minerva Neurosciences is facing several major challenges that could ultimately impact its financial performance and stock performance. Despite potential for its product candidate, Roluperidone, to become a blockbuster treatment for schizophrenia, there is a lack of treatment options for negative symptoms and potential for global expansion. However, the company faces regulatory and litigation risks, and a missed Phase 3 study, which could delay or prevent approval and commercialization of its lead candidate. Additionally, the company has incurred significant warrant issuance costs, raising concerns about its capital and financial stability.

Minerva Neurosciences (NERV) has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 50% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Minerva Neurosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Minerva Neurosciences (NERV) Forecast

Analysts have given Minerva Neurosciences (NERV) a Hold based on their latest research and market trends.

According to 2 analysts, Minerva Neurosciences (NERV) has a Hold consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Minerva Neurosciences (NERV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.